Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Session Icons
Live Streamed
On Demand
538 Views
Favorite
Facebook
Tweet
Print
Session: New Antimicrobials in the Pipeline
48 - Clinical Validation and Mechanistic Understanding of Novel DNA pol IIIC Inhibitors to treat Gram-positive Bacterial Infections: Ibezapolstat advancing into global Phase 3 Clinical Trials for C. difficile Infection
Monday, October 20, 2025
8:12 AM - 8:24 AM
US ET
Location: B302-B304
Industry Presenter(s)
Robert J. DeLuccia
Executive Chairman
Acurx Pharmaceuticals, Inc.
White Plains, NY, United States
Slides